Table 1. Participant Characteristics.
| Characteristic | No. (%) | ||
|---|---|---|---|
| All patients (N = 167) | Patients with SCLC (n = 40) | Patients with NSCLC (n = 127)a | |
| Age, median (IQR) | 66.0 (59.0-72.0) | 63.5 (59.5-69.3) | 66.0 (59.0-72.0) |
| Sex | |||
| Male | 105 (62.9) | 25 (62.5) | 80 (63.0) |
| Female | 62 (37.1) | 15 (37.5) | 47 (37.0) |
| Clinical cancer stageb | |||
| I | 17 (10.2) | 0 | 17 (13.4) |
| II | 12 (7.2) | 1 (2.5) | 11 (8.7) |
| III | 42 (25.2) | 15 (37.5) | 27 (21.3) |
| IV | 93 (55.7) | 23 (57.5) | 70 (55.1) |
| Unknown | 3 (1.8) | 1 (2.5) | 2 (1.6) |
| Metastases | |||
| No | 72 (43.1) | 16 (40.0) | 56 (44.1) |
| Yes | 93 (55.7) | 23 (57.5) | 70 (55.1) |
| Unknown | 2 (1.2) | 1 (2.5) | 1 (0.8) |
| Site of metastases | |||
| Lung, pleura, and/or pericardium (M1a) | 70 (41.9) | 16 (40.0) | 54 (42.5) |
| Visceral | 38 (22.8) | 13 (32.5) | 25 (19.7) |
| Bones | 21 (12.6) | 6 (15.0) | 15 (11.8) |
| Distant lymph nodes | 20 (12.0) | 8 (20.0) | 12 (9.4) |
| Soft tissue | 7 (4.2) | 2 (5.0) | 5 (3.9) |
| Brain | 13 (7.8) | 3 (7.5) | 10 (7.9) |
| Treatment | |||
| Chemotherapyc | 91 (54.5) | 27 (67.5) | 64 (50.4) |
| Radiotherapyd | 47 (28.1) | 14 (35.0) | 33 (26.0) |
| Surgery of primary tumore | 38 (22.8) | 1 (2.5) | 37 (29.1) |
| Surgery of metastases | 5 (3.0) | 0 | 5 (3.9) |
| Targeted therapyf | 8 (4.8) | 0 | 8 (6.3) |
| Immunotherapy (IVIG) | 3 (1.8) | 2 (5.0) | 1 (0.8) |
| Time since initial diagnosis, median (IQR), mo | 2.0 (1.0-5.5) | 1.0 (1.0-5.0) | 2.0 (1.0-6.5) |
| Other current or previous cancer | 38 (22.8) | 8 (20.0) | 30 (23.6) |
| Lung cancerg | 10 (6.0) | 1 (2.5) | 9 (7.1) |
| Other cancer | 28 (16.8) | 7 (17.5) | 21 (16.5) |
| Family history of cancer | 55/101 (54.5) | 16/28 (57.1) | 39/73 (53.4) |
| Medical history | |||
| Smokingh | 148 (88.6) | 37 (92.5) | 111 (87.4) |
| Pack-years, median (IQR) | 40.0 (30.0-50.0) | 40.0 (30.0-50.0) | 40.0 (30.0-50.0) |
| Arterial hypertension | 110 (65.9) | 23 (57.5) | 87 (68.5) |
| Pulmonary disease | 90 (53.9) | 17 (42.5) | 73 (57.5) |
| Cardiovascular disease | 84 (50.3) | 15 (37.5) | 69 (54.3) |
| Gastrointestinal disease | 51 (30.5) | 9 (22.5) | 42 (33.1) |
| Neurological disease | 43 (25.7) | 15 (37.5) | 28 (22.0) |
| Diabetes | 42 (25.1) | 9 (22.5) | 33 (26.0) |
| Urological or nephrological disease | 41 (24.6) | 8 (20.0) | 33 (26.0) |
| Thyroid disease | 39 (23.4) | 11 (27.5) | 28 (22.0) |
| Psychiatric disease | 16 (9.6) | 6 (15.0) | 10 (7.9) |
| Autoimmune disease | 9 (5.4) | 2 (5.0) | 7 (5.5) |
| Rheumatic disease | 6 (3.6) | 2 (5.0) | 4 (3.1) |
| Paraneoplastic disease | 10 (6.0) | 8 (20.0) | 2 (1.6) |
| Autoantibody-associated PNS | 6 (3.6) | 6 (15.0) | 0 |
| SIADH | 2 (1.2) | 2 (5.0) | 0 |
| Hypercalcemia | 2 (1.2) | 0 | 2 (1.6) |
Abbreviations: IQR, interquartile range; IVIG, intravenous immunoglobin; NSCLC, non–small cell lung cancer; PNS, paraneoplastic neurological syndrome; SCLC, small cell lung cancer; SIADH, syndrome of inappropriate antidiuretic hormone secretion.
Among 127 patients with NSCLC, 62 (48.8%) had adenocarcinoma, 43 (33.9%) had squamous cell carcinoma, and 22 (17.3%) had other cancers, including 2 patients (1.6%) with large cell carcinoma, 1 patient (0.8%) with large cell neuroendocrine carcinoma, 2 patients (1.6%) with typical carcinoid tumors, 1 patient (0.8%) with atypical carcinoid tumors, and 16 patients (12.6%) with NSCLC not otherwise specified.
Based on 2010 cancer staging criteria from the Union for International Cancer Control.
A total of 58 patients (34.7%) were currently receiving chemotherapy.
A total of 47 patients (28.1%) had local radiotherapy (primary tumor), and 10 patients (6.0%) had brain radiotherapy.
A total of 31 patients (18.6%) had a resection margin of R0, 3 patients (1.8%) had a resection margin of R1, 4 patients (2.4%) had an unknown resection margin.
A total of 3 patients (1.8%) received bevacizumab (vascular endothelial growth factor antibody) therapy, 2 patients (1.2%) received nintedanib (tyrosine kinase inhibitor) therapy, and 3 patients (1.8%) received other therapy.
A total of 6 patients (3.6%) had a history of lung cancer (cured), and 4 patients (2.4%) had synchronous second carcinoma.
Data on smoking were missing for 8 patients.